NEWS & PERSPECTIVE

Olaparib demonstrates a maintained response in newly diagnosed patients with advanced BRCA-mutant ovarian cancer

OBSTETRICS & GYNECOLOGY ONCOLOGY
31 Dec 2021
Get access to our exclusive articles.
Related Articles

Improved prediction of PARPi responders in ovarian cancer patients using the Leuven PARPi benefit test

Poly (ADP-ribose)-polymerase inhibitors (PARPis) like olaparib have transformed the treatment landscape for high-grade serous ovarian cancer, with multiple trials showing significant improvement in progression-free survival (PFS).1 Although PFS benefits with PARPis appear to be consistent in patient
OBSTETRICS & GYNECOLOGY ONCOLOGY
26 Apr 2024

Olaparib lengthens the survival for men with metastatic castration-resistant prostate cancer compared to new hormone agents

Loss-of-function alterations in homologous recombination repair (HRR) genes are associated with more aggressive prostate cancer and sensitivity to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition treatment.1

NEUROLOGY
31 Aug 2020

Change in direction for mCRPC therapy with parp inhibitors

Multiple systemic options have been considered for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Despite significant advances in these therapies, the median overall survival (OS) in the first-line setting is only 3 years.1,2
ONCOLOGY UROLOGY
29 Feb 2020